Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

IMC-I109V studied for the treatment of non-cirrhotic HBeAg-negative chronic hepatitis B (HBV) infection

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 May 2021) Immunocore Holdings Plc (Nasdaq: IMCR) (or the “Company”), a pioneering, clinical‐stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announces the dosing of the first patient in the first-in-human clinical trial of IMC-I109V, a new class of bispecific protein immunotherapy that is being developed for the treatment of patients with chronic hepatitis B (HBV) infection (CHB). Wholly owned IMC-I109V is the first candidate in development using Immunocore’s immune‐mobilising monoclonal T cell receptors against virus (ImmTAV®) platform to enter clinical trials.